X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ONCT-534 is a dual-action androgen receptor inhibitor, which is under phase 1/2 clinical development for the treatment of R/R metastatic castration-resistant prostate cancer.
Lead Product(s): ONCT-534
Therapeutic Area: Oncology Product Name: ONCT-534
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2024
Details:
ONCT-534 is a dual-action androgen receptor inhibitor, which is under phase 1/2 clinical development for the treatment of R/R metastatic castration-resistant prostate cancer.
Lead Product(s): ONCT-534
Therapeutic Area: Oncology Product Name: ONCT-534
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1). It is being evaluated for the treatment of relapsed or refractory aggressive b-cell lymphoma.
Lead Product(s): ONCT-808
Therapeutic Area: Oncology Product Name: ONCT-808
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 26, 2023
Details:
ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) that interacts with both the N-terminal domain and the ligand-binding domain (LBD) of the androgen receptor (AR), inhibiting cell growth and inducing AR degradation.
Lead Product(s): ONCT-534
Therapeutic Area: Oncology Product Name: ONCT-534
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) that interacts with both the N-terminal domain and the ligand-binding domain (LBD) of the androgen receptor (AR), inhibiting cell growth and inducing AR degradation.
Lead Product(s): ONCT-534
Therapeutic Area: Oncology Product Name: ONCT-534
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
ONCT-808, a ROR1 targeting autologous CAR T cell therapy, is being tested in a Phase 1/2 clinical trial for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including those who have failed previous CD19 CAR T therapy.
Lead Product(s): ONCT-808
Therapeutic Area: Oncology Product Name: ONCT-808
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
Zilovertamab (UC-961) continues to be evaluated in an ongoing Phase 1/2 study in combination with ibrutinib for the treatment of patients with MCL and chronic lymphocytic leukemia (CLL), and this trial was recently amended to include patients with marginal zone lymphoma.
Lead Product(s): Zilovertamab,Ibrutinib
Therapeutic Area: Oncology Product Name: UC-961
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
ONCT-808, an autologous chimeric antigen receptor (CAR) T therapy targeting ROR1, in patients with aggressive B cell non-Hodgkin’s lymphoma (B NHL), including those who have failed previous CD19 CAR T treatment.
Lead Product(s): ONCT-808
Therapeutic Area: Oncology Product Name: ONCT-808
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
Patients with such an inadequate response (PR or SD) will be randomized (1:1) to receive zilovertamab (UC961) (600mg administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter) or placebo, while continuing to receive oral ibrutinib.
Lead Product(s): Zilovertamab,Ibrutinib
Therapeutic Area: Oncology Product Name: UC961
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022
Details:
Under the terms of the collaboration, the supply of ibrutinib will support the company’s global registrational Phase 3 clinical trial of zilovertamab for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL), ZILO-301.
Lead Product(s): Zilovertamab,Ibrutinib
Therapeutic Area: Oncology Product Name: UC961
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pharmacyclics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
